

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/243186 A1

(51) International Patent Classification:

A61K 9/48 (2006.01) *A61P 35/00* (2006.01)
A61K 9/14 (2006.01) *C07D 401/14* (2006.01)
A61K 31/506 (2006.01) *A61K 9/46* (2006.01)

(21) International Application Number:

PCT/US2021/034811

(22) International Filing Date:

28 May 2021 (28.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/032,030 29 May 2020 (29.05.2020) US

(71) Applicant: **BLUEPRINT MEDICINES CORPORATION** [US/US]; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **WAETZIG, Joshua**; c/o Blueprint Medicines Corporation, 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **WILKIE, Gordon D.**; c/o Blueprint Medicines Corporation, 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **MAZAIK, Debra L.**; c/o Blueprint Medicines Corporation, 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **VARGA, Csanad M.**; c/o Blueprint Medicines Corporation, 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **ROGAL, Lia**; c/o Blueprint Medicines Corporation, 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **MACEACHERN, Lauren**; c/o Solid State Pharma Inc., 1489 Hollis Street, Suite 300, Halifax,

Nova Scotia B3J3M5 (CA). **MILLER, Kimberly Jean**; c/o Solid State Pharma Inc., 1489 Hollis Street, Suite 300, Halifax, Nova Scotia B3J3M5 (CA). **RIGBY-SINGLETON, Shellie**; c/o Catalent Nottingham Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX (GB). **BARKER, Ian A.**; c/o Catalent Nottingham Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX (GB). **HARRIS, Robert J.**; c/o Catalent Nottingham Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX (GB). **SPENCELEY, Aimee J.**; c/o Catalent Nottingham Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX (GB). **GORDHAN, Dipak**; c/o Catalent Nottingham Limited, 8 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX (GB).

(74) Agent: **KANEKO, Miho**; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: PRALSETINIB PHARMACEUTICAL COMPOSITIONS




FIG. 1A

(57) Abstract: The present disclosure relates to pharmaceutical composition comprising 1) an amorphous solid dispersion comprising pralsetinib, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable hydrophilic polymer; and 2) an effervescent couple; and crystalline forms of pralsetinib and pralsetinib hydrochloride salt, which are useful as RET selective inhibitors. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.

[Continued on next page]



WO 2021/243186 A1

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*